AstraZeneca
AstraZeneca sells Amrimidx and Casodex European rights to Juvisé Pharmaceuticals
December 20, 2019Medical Communications AstraZeneca, Cancer, Juvise, breast cancer, prostate cancer
AstraZeneca has announced that it has agreed to sell the rights to Arimidex (anastrozole) and Casodex (bicalutamide) in Europe, as …
AstraZeneca Vietnam obtains license to import pharmaceuticals
December 19, 2019Business Services AstraZeneca, AstraZeneca Vietnam, Vietnamese, vietnam
AstraZeneca Vietnam Co. Ltd becomes only the second multinational company in the country to obtain a license to import pharmaceuticals. …
FDA advisory committee approves the use of Lynparza in pancreatic cancer
December 18, 2019Research and Development AstraZeneca, Cancer, Merck, Pancreatic cancer, lynparza
The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of AstraZeneca and Merck’s Lynparza (olaparib) to treat pancreatic …
China approves AstraZeneca’s Imfinzi for advanced non-small cell lung cancer
December 12, 2019Sales and Marketing AstraZeneca, Imfinzi, pharma
AstraZeneca’s Imfinzi (durvalumab) is set to be made available in China after the country’s National Medical Products Administration (NMPA) decided …
AstraZeneca’s trial of leukaemia drug Calquence yields positive results
December 9, 2019Sales and Marketing AstraZeneca, Calquence, leukaemia, phase 3
AstraZeneca confirmed it had recorded positive results from its Phase 3 trial of Calquence plus obinutuzumab in leukaemia. The trial …
AstraZeneca sells US/Canada rights for Seroquel for $41 million to “focus on main therapy areas”
December 3, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, pharma
AstraZeneca has announced its intention to jettison the rights to two non-core drugs in the US and Canada in order …
FDA gives priority review for AstraZeneca’s Imfinzi
November 29, 2019Medical Communications AstraZeneca, Cancer, FDA, Imfinzi, lung cancer
The FDA has granted a priority review of AstraZeneca’s cancer treatment drug Imfinzi (durvalumab) for treatment of patients with untreated …
Drugmakers cut prices by 61% to get on Chinese reimbursement list
November 28, 2019Manufacturing and Production AstraZeneca, China, China National Reimbursement Scheme, Novartis, Roche Holding
AstraZeneca and Roche Holding are among a number of drugmakers to cut their prices in order to get on China’s …
AstraZeneca’s Qtrilment scores European authorisation in type 2 diabetes
November 15, 2019Medical Communications, Sales and Marketing AstraZeneca, EU, Europe, Qtrilmet, diabetes, pharma, type 2 diabetes
Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) has secured approval in Europe, its manufacturer AstraZeneca has revealed, as a therapy to …
AstraZeneca’s roxadustat boosts haemoglobin levels in two Phase 3 trials
November 8, 2019Medical Communications, Research and Development AstraZeneca, pharma, roxadustat
AstraZeneca’s hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) roxadustat has made a strong showing in the treatment of deficient haemoglobin (Hb) …
AstraZeneca reveals three-pronged “large-scale” R&D initiatives in China
November 7, 2019Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, China
AstraZeneca has doubled down on its commitment to the Chinese region with the announcement of three “large-scale initiatives” in the …
AstraZeneca’s Imfinzi triple combo beats chemo in treatment-naive metastatic lung cancer
October 29, 2019Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, NSCLC, lung cancer, pharma
AstraZeneca has unveiled positive new Phase 3 data for the combination of Imfinzi (durvalumab) and anti-CTLA4 antibody tremelimumab with chemotherapy …
FDA approves single-use auto-injector form of IL-5 inhibitor Fasenra
October 4, 2019Medical Communications, Sales and Marketing AstraZeneca, FDA, Fasenra, pharma
AstraZeneca is celebrating as the FDA announced the approval of its IL-5 inhibitor Fasenra (benralizumab) in a pre-filled, single-use auto-injector …
AZ’s Tagrisso extends median overall survival by over 3 years in metastatic, EGFR-mutated lung cancer
September 30, 2019Research and Development, Sales and Marketing AstraZeneca, Cancer, ESMO 2019, Tagrisso, lung cancer, pharma
AstraZeneca took to the stage at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona to present new …
New agreement gives AstraZeneca full responsibility for Linzess in China
September 18, 2019Research and Development AstraZeneca, IBS-C, Linzess
AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals in China for Linzess (linaclotide), a first-in-class new treatment for patients …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
